NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $33.04 -0.49 (-1.46%) Closing price 09/9/2026 04:00 PM EasternExtended Trading$32.89 -0.15 (-0.45%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Genmab A/S Stock (NASDAQ:GMAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$32.98▼$33.7550-Day Range$27.91▼$34.4152-Week Range$23.62▼$35.43Volume2.13 million shsAverage Volume2.49 million shsMarket Capitalization$20.61 billionP/E Ratio26.02Dividend YieldN/APrice Target$39.50Consensus RatingModerate Buy Company Overview Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering, developing and commercializing differentiated antibody-based medicines. The company’s research platforms include technologies designed to create human antibodies and bispecific antibodies that engage the immune system to target cancer and other serious diseases. Genmab’s products and partnered medicines include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; Kesimpta (ofatumumab) for multiple sclerosis, developed with Novartis; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Pfizer. The company has also collaborated with AbbVie on EPKINLY (epcoritamab), a treatment for certain B-cell malignancies. Genmab continues to advance its own pipeline and additional partnered programs in oncology and immunology. Founded in 1999, Genmab serves global markets through research, development and commercial collaborations spanning North America, Europe and other international regions. Jan van de Winkel has served as the company’s chief executive officer since 2010. Genmab’s shares trade on Nasdaq Copenhagen, and its American depositary shares trade on Nasdaq under the symbol GMAB.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreGMAB MarketRank™: Genmab A/S scored higher than 75% of companies evaluated by MarketBeat, and ranked 173rd out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingGenmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialGenmab A/S has a consensus price target of $39.50, representing about 19.6% upside from its current price of $33.04.Amount of Analyst CoverageGenmab A/S has only been the subject of 4 research reports in the past 90 days.Read more about Genmab A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth35.90% Earnings GrowthEarnings for Genmab A/S are expected to grow by 35.90% in the coming year, from $1.17 to $1.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 26.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 26.02, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.79.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.89. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.24% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 2.73, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 2.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.10 News SentimentGenmab A/S has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Genmab A/S this week, compared to 6 articles on an average week.Search Interest6 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by Institutions7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Stock News HeadlinesCritical Analysis: Whitehawk Therapeutics (NASDAQ:WHWK) & Genmab A/S (NASDAQ:GMAB)September 9 at 2:14 AM | americanbankingnews.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseSeptember 8 at 2:44 PM | globenewswire.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets. | Paradigm Press (Ad)Notice to Convene an Extraordinary General Meeting of Genmab A/SSeptember 8 at 6:00 AM | globenewswire.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of "Moderate Buy" by BrokeragesSeptember 6, 2026 | americanbankingnews.comGenmab to Participate in Upcoming Investor ConferencesAugust 25, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (GMAB), Irhythm Technologies (IRTC) and Editas Medicine (EDIT)August 9, 2026 | theglobeandmail.comGenmab Stock Rises 4.4% as Drug Royalties Lift OutlookAugust 7, 2026 | uk.finance.yahoo.comSee More Headlines GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $30.80 at the beginning of 2026. Since then, GMAB stock has increased by 7.3% and is now trading at $33.04. How were Genmab A/S's earnings last quarter? Genmab A/S Sponsored ADR (NASDAQ:GMAB) released its quarterly earnings results on Thursday, August, 6th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.37 by $0.17. The company earned $1.16 billion during the quarter, compared to analysts' expectations of $1.12 billion. Genmab A/S had a trailing twelve-month return on equity of 14.89% and a net margin of 19.08%. Read the conference call transcript. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Genmab A/S's top institutional investors include Tidal Investments LLC (0.03%), Legacy Wealth Asset Management LLC (0.02%), WINTON GROUP Ltd (0.01%) and Headlands Technologies LLC. How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG). Company Calendar Last Earnings8/06/2026Today9/10/2026Morgan Stanley 24th Annual Global Healthcare Conference9/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GMAB's financial health is in the Green zone, according to TradeSmith. GMAB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GMAB CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees3,119Year Founded1999Price Target and Rating Average Price Target for Genmab A/S$39.50 High Price Target$43.00 Low Price Target$32.00 Potential Upside/Downside+19.6%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$1.27 Trailing P/E Ratio26.02 Forward P/E Ratio28.24 P/E Growth1.89Net Income$963 million Net Margins19.08% Pretax Margin21.93% Return on Equity14.89% Return on Assets7.73% Debt Debt-to-Equity Ratio0.81 Current Ratio2.46 Quick Ratio2.44 Sales & Book Value Annual Sales$3.72 billion Price / Sales5.54 Cash Flow$1.59 per share Price / Cash Flow20.83 Book Value$9.10 per share Price / Book3.63Miscellaneous Outstanding Shares623,780,000Free Float614,172,000Market Cap$20.61 billion OptionableOptionable Beta0.84 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GMAB) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredJon Najarian's #1 Energy Trade for 2026Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...Banyan Hill Publishing | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
